Inhibikase Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Inhibikase Therapeutics Current Ratio Growth & History (IKT)
Inhibikase Therapeutics's current ratio was 21.70 for fiscal 2025.
View full Inhibikase Therapeutics company overviewInhibikase Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 21.70 | −4.67 | −17.72% |
| 2024 | 2024-12-31 | 26.37 | 22.24 | +538.05% |
| 2023 | 2023-12-31 | 4.13 | −2.46 | −37.33% |
| 2022 | 2022-12-31 | 6.59 | −3.88 | −37.04% |
| 2021 | 2021-12-31 | 10.47 | 7.34 | +234.59% |
| 2020 | 2020-12-31 | 3.13 | — | — |
Inhibikase Therapeutics quarterly current ratio
Q4.20
Q1.21
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 15.82 | 5.73 | +56.81% |
| Q1 2026 | 2026-03-31 | 30.14 | 19.13 | +173.72% |
| Q4 2025 | 2025-12-31 | 21.70 | −4.67 | −17.72% |
| Q3 2025 | 2025-09-30 | 11.73 | 10.87 | +1273.64% |
| Q2 2025 | 2025-06-30 | 10.09 | 7.77 | +334.53% |
| Q1 2025 | 2025-03-31 | 11.01 | 8.46 | +331.33% |
| Q4 2024 | 2024-12-31 | 26.37 | 22.24 | +538.05% |
| Q3 2024 | 2024-09-30 | 0.85 | −5.55 | −86.66% |
| Q2 2024 | 2024-06-30 | 2.32 | −5.72 | −71.13% |
| Q1 2024 | 2024-03-31 | 2.55 | −7.82 | −75.38% |
| Q4 2023 | 2023-12-31 | 4.13 | −2.46 | −37.33% |
| Q3 2023 | 2023-09-30 | 6.40 | −2.31 | −26.51% |
| Q2 2023 | 2023-06-30 | 8.04 | — | — |
| Q1 2023 | 2023-03-31 | 10.37 | — | — |
| Q4 2022 | 2022-12-31 | 6.59 | −3.88 | −37.04% |
| Q3 2022 | 2022-09-30 | 8.71 | — | — |
| Q4 2021 | 2021-12-31 | 10.47 | 7.34 | +234.59% |
| Q1 2021 | 2021-03-31 | 3.31 | — | — |
| Q4 2020 | 2020-12-31 | 3.13 | — | — |
Inhibikase Therapeutics current ratio trends
Over the last five fiscal years, Inhibikase Therapeutics's current ratio increased from 3.13 to 21.70, a change of 18.57. The latest reported quarter, Q2 2026, shows 15.82.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics source filings ↗